FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance

FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner

(2011) Jamila Laoukili et al.   CELL CYCLE

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer

(2009) Hiroko Yamashita et al.   CANCER SCIENCE

Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer

(2009) U. B. McGovern et al.   MOLECULAR CANCER THERAPEUTICS

Resistance to Antiestrogen Arzoxifene Is Mediated by Overexpression of Cyclin D1

(2009) Wilbert Zwart et al.   MOLECULAR ENDOCRINOLOGY

Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists

(2008) Y. Wang et al.   CANCER RESEARCH

Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions

(2008) Paul E. Goss et al.   Clinical Breast Cancer

Current research topics in endocrine therapy for breast cancer

(2008) Hiroko Yamashita   International Journal of Clinical Oncology

Activation of FoxM1 during G2 Requires Cyclin A/Cdk-Dependent Relief of Autorepression by the FoxM1 N-Terminal Domain

(2008) J. Laoukili et al.   MOLECULAR AND CELLULAR BIOLOGY

Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression

(2008) J. M-M. Kwok et al.   MOLECULAR CANCER THERAPEUTICS

Prognostic Breast Cancer Signature Identified from 3D Culture Model Accurately Predicts Clinical Outcome across Independent Datasets

(2008) Katherine J. Martin et al.   PLoS One